Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Patent
1996-06-07
1999-09-28
Naff, David M.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
435325, 435373, 435404, A01N 6300, C12N 500, C12N 502
Patent
active
059584041
ABSTRACT:
A method of treating a disease is provided that results from a deficiency of a biological factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. A method of treating diabetes mellitus is carried out by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is also carried out. A method of co-localizing islet cells with Sertoli cells and the use of the co-localized product for treating diabetes mellitus is further provided. Further described is a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is also provided. In addition, a pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is provided.
REFERENCES:
Akerstrom et al "Physiolog. Effects of 125 Dihydroxyvit." Am J. Physiol. 262 (6 Part 1). 1992 abstr. only.
Selawry, et al. (Nov. 1991) "Production of a Factor, or Factors, Suppressing IL-2 Production and T Cell Proliferation by Sertoli Cell-Enriched Preparations. A Potential Role for Islet Transplantation in an Immunologically Privileged Site", Transplantation 52(5):846-850.
Oonk, et al. (1988) "Insulin-Like Growth Factor I (IGF-I) Receptors on Sertoli Cells from Immature Rats and Age-Dependent Testicular Binding of IGF-I and Insulin", Molecular and Cellular Endocrinology 55:33-43.
Whitmore III, et al. (Oct. 1985) "The Role of Germinal Epithelium and Spermatogenesis in the Privileged Survival of Intratesticular Grafts", The Journal of Urology 134(4):782-786.
Hofmann, et al. (Aug. 1992), Abstract No. 92347475 "Immortalization of Germ Cells and Somatic Testicular Cells Using the SV40 Large T Antigen", Experimental Cell Research 201(2):417-435.
Lejeune, et al. (1993), Abstract No. 93:280614 "Enhancement of Testosterone Secretion by Normal Adult Human Leydig Cells b Co-Culture with Enriched Preparations of Normal Adult Human Sertoli Cells", Int. J. Androl. 16(1):27-34.
Berends, et al. (1991), Abstract No. 92:167853 "Significant Improvement of the Survival of Seminoma Cells in vitro by use of a Rat Sertoli Cell Feeder Layer and Serum-Free Medium", J. Natl. Cancer Inst. 83(19):1400-1403.
Carreau, et al. (1988), Abstract No. 88:227147 "Stimulation of Adult Rat Leydig Cell Aromatase Activity by a Sertoli Cell Factor", Endocrinology 122(3):1103-1109.
Naff David M.
Research Corporation Technologies Inc.
Ware Deborah K.
LandOfFree
Treatment methods for disease using co-localized cells and Serto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment methods for disease using co-localized cells and Serto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment methods for disease using co-localized cells and Serto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-700107